Giuseppe Gullo
Dublin, L, Ireland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 52 publications
Assessment of cybersickness induced by augmented reality ultrasound procedures using head-mounted display.
Journal: Frontiers in digital health
Published: February 04, 2026
Augmented-reality enhanced ultrasound guidance: a sterile, hands-free approach using commercial augmented reality headsets.
Journal: Radiological physics and technology
Published: October 05, 2025
Chromosome centromere copy number amplification associated with exceptional response in HER2-positive metastatic breast cancer patients.
Journal: Oncogene
Published: October 01, 2025
Clinical Interchangeability of PD-L1 Immunohistochemistry Assays in First-Line Non-Small Cell Lung Cancer Management With Cemiplimab.
Journal: JCO precision oncology
Published: September 24, 2025
Reproducibility and precision of renal perfusion quantification with contrast enhanced ultrasound in critically ill patients: a prospective observational study.
Journal: Critical care (London, England)
Published: July 18, 2025
Prognostic value of patient-reported outcomes for survival in patients with advanced lung cancer receiving immune checkpoint inhibitors.
Journal: Frontiers in immunology
Published: June 03, 2025
TCHL - a phase II neo-adjuvant study assessing TCH (docetaxel, carboplatin and trastuzumab) and TCHL (docetaxel, carboplatin, trastuzumab and lapatinib) in HER-2 positive breast cancer patients: a 5-year follow-up with serum biomarker analysis.
Journal: Acta oncologica (Stockholm, Sweden)
Published: February 11, 2025
Peripheral blood cells as prognostic markers in patients with advanced non-small cell lung cancer treated with cemiplimab as monotherapy or in combination with chemotherapy.
Journal: Cancer treatment and research communications
Published: January 14, 2025
Sagittal Parameters and Clinical Outcomes in Cervical Spondylitis: The Cohort Analysis.
Journal: Diseases (Basel, Switzerland)
Published: January 12, 2025
Cemiplimab monotherapy as first-line treatment of patients with brain metastases from advanced non-small cell lung cancer with programmed cell death-ligand 1 ≥50.
Journal: Cancer
Published: August 16, 2024
Phase I Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced Melanoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 20, 2024
First-in-Human Dose-Escalation Study of Fianlimab, an Antilymphocyte Activation Gene-3 Antibody, with Cemiplimab in Patients with Advanced Malignancies.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 02, 2024
Last Updated: 09/26/2026